University of Michigan Rogel Cancer Center

Last updated
The Rogel Cancer Center building CU Sign.jpg
The Rogel Cancer Center building

The University of Michigan Rogel Cancer Center is a cancer research and treatment institution based in Ann Arbor, Michigan, United States. The Rogel Cancer Center is affiliated with the University of Michigan and Michigan Medicine.

Contents

History

The Rogel Cancer Center was founded in 1986 at the University of Michigan. In 1988, it was designated as part of the National Cancer Institute cancer centers program. It received comprehensive cancer center status in 1991 and continues to be an NCI-designated comprehensive cancer center today. [1]

From 1991-2018, it was known as the University of Michigan Comprehensive Cancer Center. The center was renamed the Rogel Cancer Center in 2018 in recognition of a $150 million commitment from Richard and Susan Rogel. [2]

The Rogel Cancer Center is ranked among the top cancer programs by U.S. News & World Report. [3] In addition to being an NCI-designated comprehensive cancer center, it is a founding member of the National Comprehensive Cancer Network [4]

The center’s founding director was Max Wicha, a medical oncologist and researcher who was part of the team to first discover cancer stem cells in a solid tumor. [5] Wicha served as director for 27 years. He was succeeded by Theodore Lawrence in 2015 and by Eric Fearon in 2016. Fearon is a nationally recognized investigator in cancer genetics whose research has led to a greater understanding of the gene defects that cause colon and rectal cancer to develop and spread. [6]

Scientific programs

Research at the Rogel Cancer Center is divided into six basic, clinical and population science programs: [7]

Accomplishments

Significant cancer research discoveries from the Rogel Cancer Center include:

Related Research Articles

<span class="mw-page-title-main">Kidney cancer</span> Medical condition

Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Symptoms may include blood in the urine, a lump in the abdomen, or back pain. Fever, weight loss, and tiredness may also occur. Complications can include spread to the lungs or brain.

<span class="mw-page-title-main">Harold E. Varmus</span> American scientist (born 1939)

Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

Cancer staging is the process of determining the extent to which a cancer has grown and spread. A number from I to IV is assigned, with I being an isolated cancer and IV being a cancer that has metastasized and spread from its origin. The stage generally takes into account the size of a tumor, whether it has invaded adjacent organs, how many regional (nearby) lymph nodes it has spread to, and whether it has appeared in more distant locations (metastasized).

Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

Fox Chase Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital located in the Fox Chase section of Philadelphia, Pennsylvania, United States. The main facilities of the center are located on property adjoining Burholme Park. The center is part of the Temple University Health System (TUHS) and specializes in the treatment and prevention of cancer.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

National Comprehensive Cancer Network (NCCN) is an alliance of 33 cancer centers in the United States, most of which are designated by the National Cancer Institute as comprehensive cancer centers. It is a non-profit organization with offices in Plymouth Meeting, Pennsylvania. John W. Sweetenham, MD, FRCP, FACP, FASCO, from UT Southwestern Simmons Comprehensive Cancer Center, is chairman of the NCCN Board of Directors. It publishes the peer-reviewed medical journal Journal of the National Comprehensive Cancer Network.

The Cancer Genome Atlas (TCGA) is a project to catalogue the genetic mutations responsible for cancer using genome sequencing and bioinformatics. The overarching goal was to apply high-throughput genome analysis techniques to improve the ability to diagnose, treat, and prevent cancer through a better understanding of the genetic basis of the disease.

<span class="mw-page-title-main">Wilms tumor protein</span> Transcription factor gene involved in the urogenital system

Wilms tumor protein (WT33) is a protein that in humans is encoded by the WT1 gene on chromosome 11p.

<span class="mw-page-title-main">Sean J. Morrison</span>

Sean J. Morrison is a Canadian-American stem cell biologist and cancer researcher. Morrison is the director of Children's Medical Center Research Institute at UT Southwestern, a nonprofit research institute established in 2011 as a joint venture between Children’

Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells. It is a biochemical laboratory method for the characterization and identification of the DNA or RNA sequences of cancer cell(s).

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

Measles virus encoding the human thyroidal sodium iodide symporter or MV-NIS is an attenuated oncolytic Edmonston (Ed) strain of measles virus.

<span class="mw-page-title-main">Yihai Cao</span> Chinese-born Swedish scientist and professor

Yihai Cao, M.D., hM. D., Ph.D., is a Chinese-born Swedish scientist and a professor at the Karolinska Institute, Sweden. He is also an honorary professor/guest professor in Copenhagen University, Denmark; Linköping University, Sweden; Leicester University, UK; Shinshu University, Japan; Shandong University, China; and Peking University, China. He is an internationally recognized and cited researcher in cancer, obesity, diabetes, cardiovascular disease, and eye disease research. His publications have been cited more than 35,000 times and his h-index is 92. Cao received the Fernström research prize, the Karolinska distinguished professor award, and the Axel Hirsch Prize in medicine. Cao received an ERC-advanced research grant award, and a Novo Nordisk-advanced grant award. From 2018, Cao was elected to Academia Europaea, the European Academy of Sciences and Arts, the Chinese Academy of Engineering, the National Academy of Inventors, and The World Academy of Sciences. His research findings received broad public attentions including New York Times, Reuters and Swedish National TV broad casting.

Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

Eric Reese Fearon is an American oncologist. He is the Emanuel N. Maisel Professor of Oncology at the University of Michigan and director of the University of Michigan Rogel Cancer Center.

Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

References

  1. "NCI-Designated Cancer Centers". National Cancer Institute. 2012-04-05. Retrieved 2019-09-19.
  2. admin (2013-09-12). "Timeline". Rogel Cancer Center | University of Michigan. Retrieved 2019-08-14.
  3. "Best Hospitals for Cancer". U.S. News & World Report.
  4. "About NCCN". www.nccn.org. Retrieved 2019-08-14.
  5. 1 2 Al-Hajj, Muhammad; Wicha, Max S.; Benito-Hernandez, Adalberto; Morrison, Sean J.; Clarke, Michael F. (2003-04-01). "Prospective identification of tumorigenic breast cancer cells". Proceedings of the National Academy of Sciences of the United States of America. 100 (7): 3983–3988. doi: 10.1073/pnas.0530291100 . ISSN   0027-8424. PMC   153034 . PMID   12629218.
  6. Fearon, Eric R.; Vogelstein, Bert (1990-06-01). "A genetic model for colorectal tumorigenesis". Cell. 61 (5): 759–767. doi: 10.1016/0092-8674(90)90186-I . ISSN   0092-8674. PMID   2188735. S2CID   22975880.
  7. Anonymous (2013-08-08). "Research Programs". Rogel Cancer Center | University of Michigan. Retrieved 2019-08-14.
  8. Tomlins, Scott A; Laxman, Bharathi; Varambally, Sooryanarayana; Cao, Xuhong; Yu, Jindan; Helgeson, Beth E; Cao, Qi; Prensner, John R; Rubin, Mark A (February 2008). "Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer". Neoplasia (New York, N.Y.). 10 (2): 177–188. doi:10.1593/neo.07822. ISSN   1522-8002. PMC   2244693 . PMID   18283340.
  9. Reddy, Pavan; Koreth, John; Dinarello, Charles A.; Lewis, Eli C.; Choi, Sung Won; Yanik, Gregory A.; Parkin, Brian L.; Alyea, Edwin P.; Ho, Vincent T. (2018-01-01). "α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease". Blood. 131 (12): blood–2017–11-815746. doi:10.1182/blood-2017-11-815746. ISSN   0006-4971. PMC   5865235 . PMID   29437593.
  10. "Building a Better Mouse Model for High-Grade Serous Carcinoma". Cancer Network. September 13, 2018.
  11. Reshma Jagsi; Pottow, John A.E.; Griffith, Kent A.; Bradley, Cathy; Hamilton, Ann S.; Graff, John; Katz, Steven J.; Hawley, Sarah T. (2014-04-20). "Long-Term Financial Burden of Breast Cancer: Experiences of a Diverse Cohort of Survivors Identified Through Population-Based Registries". Journal of Clinical Oncology. 32 (12): 1269–1276. doi:10.1200/JCO.2013.53.0956. ISSN   0732-183X. PMC   3986387 . PMID   24663041.
  12. You, D.; Aryal, M.; Samuels, S. E.; Eisbruch, A.; Cao, Y. (December 2016). "Temporal Feature Extraction from DCE-MRI to Identify Poorly Perfused Subvolumes of Tumors Related to Outcomes of Radiation Therapy in Head and Neck Cancer". Tomography. 2 (4): 341–352. doi:10.18383/j.tom.2016.00199. ISSN   2379-1381. PMC   5243121 . PMID   28111634.